Literature DB >> 18006539

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

M Rudwaleit1, S Schwarzlose, E S Hilgert, J Listing, J Braun, J Sieper.   

Abstract

OBJECTIVE: To evaluate the role of MRI in predicting a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement of at least 50% (BASDAI 50) upon anti-tumour necrosis factor (TNF) therapy of active ankylosing spondylitis (AS).
METHODS: MRIs from patients with active AS who participated in randomised controlled trials were analysed with respect to presence and extent of active inflammatory lesions as detected in the spine (n = 46), sacroiliac (SI) joints (n = 42) and both sites (n = 26). Univariate and multivariate logistic regression analyses were applied to evaluate MRI and clinical data in predicting a BASDAI 50 response.
RESULTS: The Berlin MRI spine score (odds ratio (OR) 1.16, 95% CI 1.02 to 1.33) and disease duration (OR 0.9, 95% CI 0.63 to 0.97) were statistically significant predictors of a BASDAI 50 response using regression analysis while there was only a trend for C-reactive protein (CRP). The likelihood ratio (LR) for achievement of BASDAI 50 was increased in patients with a Berlin MRI spine score >/=11 (LR 6.7), disease duration <10 years (LR 4.2) and CRP >/=40 mg/litre (LR 3.4). All patients with two or three of these predictors improved clinically (as assessed by BASDAI) by at least 45%. Disease duration >20 years, normal CRP and no active inflammatory lesion in the spine were highly predictive of not achieving BASDAI 50. A trend was only found for the MRI score of SI joints to be predictive.
CONCLUSIONS: Widespread inflammation in the spine as detected by MRI contributes to predicting a BASDAI 50 response in active patients with AS treated with anti-TNF agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006539     DOI: 10.1136/ard.2007.073098

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  77 in total

1.  Ankylosing spondylitis - the changing role of imaging.

Authors:  Zoe Ash; Helena Marzo-Ortega
Journal:  Skeletal Radiol       Date:  2012-09       Impact factor: 2.199

Review 2.  Biomarkers in spondyloarthritis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

3.  Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.

Authors:  Susanne Juhl Pedersen; Merete Lund Hetland; Inge Juul Sørensen; Mikkel Ostergaard; Hans Jørgen Nielsen; Julia Sidenius Johansen
Journal:  Clin Rheumatol       Date:  2010-07-18       Impact factor: 2.980

Review 4.  A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.

Authors:  L Goh; A Samanta
Journal:  Rheumatol Int       Date:  2009-06-28       Impact factor: 2.631

Review 5.  New evidence on the management of spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy
Journal:  Nat Rev Rheumatol       Date:  2016-04-07       Impact factor: 20.543

Review 6.  [Spondyloarthritides].

Authors:  M Rudwaleit
Journal:  Internist (Berl)       Date:  2017-07       Impact factor: 0.743

Review 7.  [What is ascertained in the therapy of axial spondyloarthritis?].

Authors:  J Braun; X Baraliakos; F Heldmann; U Kiltz
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

Review 8.  Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.

Authors:  Denis Poddubnyy; Lianne S Gensler
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-11-10       Impact factor: 4.098

Review 9.  Clinical assessment and outcome research in spondyloarthritis.

Authors:  Robert B M Landewé; Astrid van Tubergen
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

10.  Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.

Authors:  Carmen Stolwijk; Marieke Pierik; Robert Landewé; Ad Masclee; Astrid van Tubergen
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.